Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA.
Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA.
Crit Care Med. 2019 Mar;47(3):e214-e221. doi: 10.1097/CCM.0000000000003631.
Increasing age is a well-recognized risk factor for in-hospital mortality in patients receiving extracorporeal membrane oxygenation for cardiogenic shock, but the shape of this relationship is unknown. In addition, the impact of age on hospital length of stay, patterns of patient disposition, and costs has been incompletely characterized.
Retrospective analysis of the National Inpatient Sample.
U.S. nonfederal hospitals, years 2004-2016.
Adults with cardiogenic shock treated with extracorporeal membrane oxygenation (3,094; weighted national estimate: 15,415).
None.
The mean age of extracorporeal membrane oxygenation recipients was 54.8 ± 15.4 years (range, 18-90 yr). Crude in-hospital mortality was 57.7%. Median time-to-death was 8 days (interquartile range, 3-17 d). A linear relationship between age and in-hospital mortality was observed with a 14% increase in the adjusted odds of in-hospital mortality for every 10-year increase in age (adjusted odds ratio, 1.14; 95% CI, 1.08-1.21; p < 0.0001). Thirty-four percent of patients were discharged alive at a median time of 30 days (interquartile range, 19-48 d). The median length of stay and total hospitalization costs were 14 days (interquartile range, [5-29 d]) and $134,573 ($71,782-$239,439), respectively, both of which differed significantly by age group (length of stay range from 17 d [18-49 yr] to 9 d [80-90 yr]; p < 0.0001 and cost range $147,548 [18-49 yr] to $105,350 [80-90 yr]; p < 0.0001).
Age is linearly associated with increasing in-hospital mortality in individuals receiving extracorporeal membrane oxygenation for cardiogenic shock without evidence of a threshold effect. Median time-to-death is approximately 1 week. One third of patients are discharged from the hospital alive, but the median time-to-discharge is 1 month. Median length of stay ranges from 9 to 17 days depending on age. Hospitalization costs exceed $100,000 in all age groups.
在接受体外膜肺氧合(ECMO)治疗心源性休克的患者中,年龄的增加是院内死亡率的一个公认的危险因素,但这种关系的形状尚不清楚。此外,年龄对住院时间长短、患者处置模式和成本的影响尚未完全描述。
国家住院患者样本的回顾性分析。
美国非联邦医院,2004 年至 2016 年。
接受 ECMO 治疗的心源性休克成人(3094 例;全国估计值为 15415 例)。
无。
ECMO 接受者的平均年龄为 54.8±15.4 岁(范围 18-90 岁)。院内死亡率为 57.7%。中位死亡时间为 8 天(四分位距 3-17 d)。观察到年龄与院内死亡率之间呈线性关系,每增加 10 岁,院内死亡率的调整比值比增加 14%(调整比值比,1.14;95%置信区间,1.08-1.21;p<0.0001)。34%的患者在中位时间 30 天(四分位距 19-48 d)时存活出院。中位住院时间和总住院费用分别为 14 天(四分位距 5-29 d)和 134573 美元(71782-239439 美元),这两个参数均按年龄组显著不同(住院时间范围为 17 天[18-49 岁]至 9 天[80-90 岁];p<0.0001,成本范围为 147548 美元[18-49 岁]至 105350 美元[80-90 岁];p<0.0001)。
年龄与接受 ECMO 治疗的心源性休克患者的院内死亡率呈线性相关,无阈值效应的证据。中位死亡时间约为 1 周。三分之一的患者从医院出院,但中位出院时间为 1 个月。住院时间中位数从 9 天到 17 天不等,具体取决于年龄。所有年龄组的住院费用均超过 10 万美元。